Blood, Tissues, Organs
Veterinary Medicines Information
How We Monitor Safety
Accessing unauthorised Veterinary Medicines
Adverse Reaction Reporting
Annual Pharmacovigilance Reports
Information for Animal Owners
Veterinary News & Events
Scientific Animal Protection
Availability of veterinary medicines in Ireland
Blood, Tissues, Organs
Suspension of marketing authorisation for Parofor 175 mg/ml solution for injection for pigs
Consequent to the
outcome of a referral procedure on veterinary medicinal products containing paromomycin that are administered by injection to pigs to the European Medicines Agency (EMA)
European Commission adopted a decision that requires Member States to suspend national marketing authorisations for the products concerned
. The procedure was undertaken to consider differences in the approved indications, dosage, and withdrawal periods in respect of similar injectable products that were authorised nationally.
Product name or type:
Parofor 175 mg/ml Solution for Injection for pigs
Safety Advisory Notice concerning the suspension of the marketing authorisation for Parofor 175 mg/ml solution for injection for pigs
Serial Or Batch Number And Expiry Date:
Huvepharma NV, Belgium
Veterinary practitioners and pharmacists
Problem Or Issue:
to the EMA that was initiated by Belgium, the
considered that the use of veterinary medicinal products containing paromomycin to be administered parenterally to pigs is not supported by pre-clinical, clinical and residue depletion data and currently recommended indications, dosing regimens and withdrawal period could pose a potential risk to animal and human health, and therefore the benefit-risk assessment is negative.
Background Information Or Related Documents:
Further documents explaining the rationale of the CVMP opinion will be uploaded to the EMA website within 4 weeks of the European Commission decision of 11 October 2019.
Actions To Be Taken:
Veterinary practitioners should not prescribe
products containing paromomycin, pending the lifting of the suspension of the marketing authorisation (which is dependent on new information being made available to address the CVMP concerns).
This is a prescription only medicine that contains an aminoglycoside antibiotic for pigs. The action being taken is a precautionary approach on the basis of inadequate information on the safety and efficacy of the product concerned. The CVMP identified a potential risk that product administration at the currently recommended dose will lead to ineffective treatment and risk of antimicrobial resistance development. The HPRA understands that the product is not being marketed currently.
Date Printed: 09/08/2022